Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Doerholt

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Journal of the International AIDS Society|June 12, 2021
No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µLAndrew Atkinson, Jose M Miro, Amanda Mocroft, et al.
The Pediatric Infectious Disease Journal|February 24, 2026
Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 TrialEva Natukunda, Alex J Szubert, Mutsa Bwakura-Dangarembizi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2010
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?, Amanda Mocroft, Peter Reiss, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 14, 2023
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 TrialHylke Waalewijn, Alexander J Szubert, Roeland E Wasmann, et al.
Plos Medicine|January 31, 2018
Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study, Ali Judd, Elizabeth Chappell, et al.
The New England Journal of Medicine|May 14, 2025
Second-Line Antiretroviral Therapy for Children Living with HIV in AfricaVictor Musiime, Mutsa Bwakura-Dangarembizi, Alexander J Szubert, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Journal of the International AIDS Society|June 12, 2021
No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µLAndrew Atkinson, Jose M Miro, Amanda Mocroft, et al.
The Pediatric Infectious Disease Journal|February 24, 2026
Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 TrialEva Natukunda, Alex J Szubert, Mutsa Bwakura-Dangarembizi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2010
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?, Amanda Mocroft, Peter Reiss, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 14, 2023
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 TrialHylke Waalewijn, Alexander J Szubert, Roeland E Wasmann, et al.
Plos Medicine|January 31, 2018
Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study, Ali Judd, Elizabeth Chappell, et al.
The New England Journal of Medicine|May 14, 2025
Second-Line Antiretroviral Therapy for Children Living with HIV in AfricaVictor Musiime, Mutsa Bwakura-Dangarembizi, Alexander J Szubert, et al.
Pageof 4